UNITY Biotechnology, Inc. is a biotechnology company focused on extending human healthspan by developing therapeutics that slow, halt, or reverse diseases of aging. The company operates in the biopharmaceutical industry, targeting age-related diseases such as osteoarthritis, eye diseases, and pulmonary diseases. UNITY's core technology involves creating senolytic medicines, which are designed to selectively eliminate senescent cells—cells that have stopped dividing and contribute to aging and chronic diseases. By removing these cells, UNITY aims to alleviate the symptoms and progression of age-related conditions.

UNITY primarily serves patients suffering from age-related diseases, with a focus on improving their quality of life and extending their healthy years. The company operates in the global healthcare market, particularly within the sectors of biotechnology and pharmaceuticals.

UNITY's business model revolves around the research, development, and commercialization of its senolytic therapies. The company generates revenue through partnerships, licensing agreements, and eventually, the sale of its therapeutic products once they receive regulatory approval. UNITY's innovative approach has attracted significant investment, including backing from high-profile investors like Jeff Bezos.

Keywords: senolytic medicines, age-related diseases, biotechnology, osteoarthritis, eye diseases, pulmonary diseases, therapeutic development, healthspan extension, chronic disease, biopharmaceutical.